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e-mail address: amm-ry@hotmail.comAli M. Al-Halafi, MD, FRCS ⇑AbstractWe are approaching a new era of retinal pharmacotherapy where new drugs are rapidly being worked out for the treatment of
posterior-segment disease. Recent development in ocular drug delivery systems research has provided new insights into drug
development, and the use of nanoparticles for drug delivery is thus a promising excellent approach for advanced therapy of ocular
diseases. The primary goal is to develop a variety of drug delivery systems to complement and further enhance the efficacy of the
available new medications. The ideal sustained release technology will provide a high level of safety with continuous release over
an extended period of time while maintaining almost total drug bioactivity.
The use of nanocarriers, such as cyclodextrin nanoparticle suspension, liposomes, nanospheres and, nanoemulsions for gene ther-
apy of retinal diseases has been highlighted in this review.
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Nanotechnology involves creation and utilization of mate-
rials, devices or systems on the nanometer scale. This field is
currently undergoing explosive development on many fronts.
The technology is expected to create innovations and play a
critical role in various biomedical applications, not only in
drug delivery, but also in molecular imaging, biomarkers
and biosensors.
The eye is a relatively isolated organ divided into anterior
and posterior segments with numerous avascular structures.1
In this regard, the efficacy of topical drug delivery via eye-
drops is only limited to the treatment of anterior segment
eye diseases. Drugs can enter the posterior segment of the
eye via three distinctive noninvasive routes: (1) through con-
junctiva/sclera after topical application; (2) from the cornea
and aqueous humor after topical application; and (3) from
the systemic circulation after topical, parenteral, oral, or
other administration routes that deliver drug to the blood
circulation.The eye, particularly the posterior segment, is composed
of tissues that are difficult for drugs to penetrate because
of structural peculiarities such as the barrier function. Thus,
many research studies on nano-sized drug carriers have been
conducted in the field of ophthalmology.2,3
In this review, the focus will be on the use of nanocarriers,
such as cyclodextrin nanoparticle suspension, liposomes,
nanospheres and nanoemulsions, and highlights the use of
nanoparticles for gene therapy of retinal diseases.What is micro and nano scale?
Nanotechnology refers to a field of science whose unifying
materials are close to molecular scale on dimensions be-
tween 1 and 1000 nm (Fig. 1). The macroscopic classification
of ophthalmic dosage forms is not related to their micro-
scopic structure and they cannot per se be defined as micro-
or nano-technology such as gel-forming solutions, powders
for solutions, ophthalmic suspensions, ophthalmic ointments,e:
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ocular inserts.4
Micro- and nano-technological drug formulations are clas-
sified according to the diameter of their particulates. Micro-
technology usually refers to technological devices with
dimensions close to 0.1–100 lm (102–105 nm) and particles
between 0.1 and 100 lm are called microparticles. Drop size
in pharmaceutical emulsions is between 0.1 and 1 lm
(102–103 nm). Microemulsions form droplets that are be-
tween 5 and 140 nm and, thus, should be more correctly re-
ferred to as nanoemulsions. Microparticles can consist of
micronized drug particles for intravitreal injection but more
often such particles consist of micronized polymer/drug ma-
trix-like structures, i.e., microspheres, or polymer-coated
microparticles.
Nanoparticles are particles with at least one dimension
less than 100 nm for example, the size of liposomes is fre-
quently between 10 and 1000 nm. Nanoparticles can refer
to nanospheres (e.g., drug/polymer matrix) or nanocapsules
(e.g., polymer-coated drug particles). Examples of nanoparti-
cles for intravitreal drug delivery include albumin nanoparti-
cles for delivery of ganciclovir and a formivirsen analog,5
and tamoxifen-loaded nanoparticles.6 Nanoclusters are
nanoparticles formed by molecular aggregation and nano-
spheres are nanoparticles where the active ingredient is
encapsulated.Figure 1. Nano scale (This picture is from http://www.tzheStructural barriers of the eye
Eye structures that function as a barrier to decrease the
permeability of the eye to pharmacological agents include
the corneal epithelium and endothelium, the sclerocorneal
parenchyma, the inner and outer blood–retinal barriers, and
the retinal inner limiting membrane.7
Drugs penetrate the epithelium either transcellularly or
paracellularly. The transcellular route predominates for lipo-
philic drug molecules whereas the paracellular route predom-
inates for hydrophilic molecules and small ions. The pore size
has been estimated to be about 1 nm (permeable for drugs
with molecular weight (MW) less than about 700 Dalton)
although studies have indicated that some pores could be
up to 5 nm in diameter.8,9 It is accepted that most drugs per-
meate the epithelium via passive diffusion and, although
drug transporters have been located in the epithelium, their
significance is still unclear.10 As a result, less than 5% of the
drug can cross the corneal barrier and gain access to the
inner eye.11–13
The endothelium is a membrane one cell layer with large
intracellular junctions. It can be considered as a leaky lipo-
philic barrier that offers no permeation resistance toward
hydrophilic drugs but may offer some resistance toward lipo-
philic drugs.14 Conjunctiva is approximately 15–25 times
more permeable than the sclera and the sclera isalth.com/health/Nanometer/2007-10-17/15240.html).
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The choroidal vasculature can contribute to drug clearance
from the eye and, thus, constitute a permeation barrier dur-
ing drug permeation from the eye surface to the retina and
vitreous. Although systematically administered drugs can
reach the choroid membrane, drug delivery into the retina
or the vitreous body is difficult to achieve through conven-
tional methods because of the presence of the blood–aque-
ous barrier and the inner and outer blood–retinal barriers in
those structures.16 Direct intravitreal injection of drugs into
the vitreous cavity is employed to achieve higher drug
concentrations in the vitreous and the retina.17–20 However,
repeated injections are required to maintain drug concentra-
tions at an effective therapeutic level over a certain period of
time because the half-life of drugs in the vitreous is relatively
short.Nanoparticles and retinal diseases
Particles can interact with cells via different mechanisms
which, in turn, results in exposure of nanoparticles to differ-
ent intra cellular environments.21
The development of a drug delivery system (DDS) that can
be used for the posterior segment of the eye that involves
nanocarriers to overcome the issue of frequent intravitreal
administration has received great consideration. In this re-
view, a description of nanocarriers used in the field of retina,
focusing on cyclodextrin nanoparticle suspension, liposomes,
nanospheres and, nanoemulsions has been provided. The use
of nanoparticles for gene therapy has also been highlighted.
Cyclodextrin
Cyclodextrin nanoparticle suspension in eye drops offers a
new and promising drug delivery method for the posterior
segment of the eye. It is effective with a variety of drugs,
including steroids and sulfonamides, such as carbonic anhy-
drase inhibitors, and may be used with many small lipophilic
molecules. Cyclodextrin derivatives which have been applied
in ophthalmology include the hydroxypropyl derivatives of b-
and c-cyclodextrin, the randomly methylated b-cyclodextrin,
and sulfobutylether b-cyclodextrin.22
Liposomes
Liposomes vesicles are 25–10,000 nm in diameter23 and,
composed of a phospholipid bilayer, and water-soluble drugs
can be incorporated into their aqueous phase, whereas lipid-
soluble drugs can be incorporated into their lipid phase.24
Their size, lipid composition, and electric charge can be easily
controlled.25 Liposomes have low antigenicity and almost no
toxicity.26 The liposome membrane structure is highly stable
and can be deformed during injection through a 27- or 30-
gauge needle.23,27 Studies have been conducted on the intra-
vitreal injection of drug-bearing liposomes and have demon-
strated that toxicity of the drug can be reduced, the half-life
of the drug inside the vitreous body can be prolonged, and
the release of the drug can be controlled.28–30 A liposome
delivery system can be used to encapsulate large antibody
fragments and even small unstable siRNA molecules without
degradation and loss of bioactivity.23,27,31 Liposome-encap-
sulated ganciclovir (GCV) is used for the treatment ofcytomegalovirus retinitis in acquired immune deficiency syn-
drome (AIDS) patients, liposome-encapsulated GCV and free
GCV were injected into the vitreous body of rabbits in a pre-
vious study.32 In contrast, no retinopathy was found in the
group that received 1 mg of liposome-encapsulated GCV,
and the concentration of the drug demonstrated therapeutic
levels up to 14 days after injection.32 In addition, previous re-
ports have shown that fewer intravitreal injections were re-
quired for liposome-encapsulated GCV than for free GCV.33
Other reports have also demonstrated the usefulness of
liposomal formulations after intravitreal injection and the
drugs delivered in these studies have included amikacin,34
amphotericin B35 a model antisense oligonucleotide36
bevacizumab,37 cyclosporine,38 5-fluorouridine 50-monophos-
phate,39,40 fluconazole,41 tacrolimus,42 tobramycin,43 vasoac-
tive intestinal peptide,44 an angiogenesis inhibitor,45
tilisolol,46 and ofloxacin.47
Nanospheres
Nanospheres are of truly uniform sizes ranging from
50 nm to 1000 nm.48 Drugs are encapsulated in synthetic
and natural polymers to permit sustained local release and
tissue targeting of the drugs. The most common substrates
are (poly lactic acid) (PLA), polyglycolic acid (PGA), and their
copolymer, and poly (lactic-co-glycolic acid) (PLGA). Injected
intravitreally PLA and PLGA do not show electrophysiological
or histological toxicity in the retina.49,50 A GCV intraocular im-
plant is the first FDA-approved sustained-release formulation
(Vitrasert; Bausch and Lomb, Rochester, NY, USA) that is
nondegradable in vivo and is being used in the treatment
of cytomegalovirus retinitis in AIDS patients. When fluores-
cent 2000 nm, 200 nm, and 50 nm nanospheres were injected
into the vitreous body of rabbits, the 2000 nm particles were
found in the intravitreal cavity and the trabecula, whereas the
200 nm and 50 nm particles were found even inside the
retina.51
Nanoemulsions
The diameter of the micelles is approximately 100 nm or
less. Micro/nanoemulsions have good tissue permeability be-
cause of the small size of the micelles and the presence of a
surfactant among the components; as a result, studies on
DDSs have been conducted mainly in the field of ophthalmic
drugs.52 The instillation of dexamethasone-containing micro-
emulsions in the eyes of rabbits has been shown to result in
enhanced intraocular permeability.53 In comparison with nan-
ospheres and liposomes, nanoemulsions are also unsuitable
for long-term sustained drug release.Nanoparticles and gene therapy
Scientists and clinicians have used nanoparticles that
contain gene transcription factors and other modulating
molecules that permit reprogramming of cells in vivo,54 as
well as nanomaterials to induce selective differentiation of
neural progenitor cells55 and to create neural–mechanical
interfaces.56–58
A tyrosine kinase mutation is present in some patients with
retinitis pigmentosa in the Royal College of Surgeons (RCS)
rats.59–61 The PCQretinal pigment epithelium of RCS rats
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properly, resulting in progressive rod and cone photorecep-
tor degeneration.62 About 585-nm-diameter basic fibroblast
growth factor (bFGF) nanoparticles using bovine gelatin
and recombinant human bFGF was prepared by Sakai et al.63
bFGF nanoparticles were still present in the outer retina after
8 weeks of intravitreal injection into RCS rat eyes.
Oxidative damage has a role in the pathogenesis of many
retinal diseases, including diabetic retinopathy, age-related
macular degeneration, retinopathy of prematurity, and
phototoxicity.25,26,64–67 Cerium oxide (CeO2) nanoparticles
(‘‘nanoceria’’) demonstrate the formation of more oxygen
vacancies in their crystal structure, particularly at 3–5 nm
diameter.28,29 As a result, nanoceria can scavenge reactive
oxygen intermediates.
Nanoparticles can deliver genes efficiently to stem cells30
and have been explored as a means for gene delivery in
the diagnosis and treatment of ocular disease.68–71 Used
DNA nanoparticles consisting of single molecules of DNA
compacted with 10-kDa polyethylene glycol (PEG)-substi-
tuted lysine 30-mer peptides containing the wild-type retinal
degeneration slow (Rds) gene, peripherin/rds, to induce cone
photoreceptor rescue in an animal model (rds+/) of human
retinitis pigmentosa with promising results.72,73
Nanoengineering of viral vectors via site-directed muta-
genesis has produced modifications of the virus capsid that
may play a role in its clinical utility. Adeno-associated viruses
(AAVs) are nonpathogenic, small, single-stranded DNA par-
vo-viruses that can transduce dividing and nondividing
cells.56 Nanoengineering of the AAV capsid may provide an
important tool for facilitating gene therapy to photorecep-
tors. Because it is a relatively immune-privileged site, subret-
inal delivery may still have some advantages in comparing
with intravitreal virus delivery.74 Subretinal virus delivery re-
quires pars plana vitrectomy and has a higher rate of compli-
cations (e.g., retinal tears) than intravitreal delivery, which can
be done in a clinical setting under topical anesthesia. Tyro-
sine-to-phenylalanine capsid AAV2 mutants showed 10- to
20-fold higher transgene expression of the entire retina after
intravitreal injection, compared to AAV with wild-type caps-
ids.75 Recombinant AAVs (rAAVs) have relatively low immu-
nogenicity, can target many nondividing cells, and can
provide sustained efficient therapeutic gene expression after
a single treatment.76 Recombinant AAVs have been used to
treat humans with Leber congenital amaurosis.77–79
Conclusion
Nanotechnology has moved into our present life with
smart materials, nanoscale biostructure and drug delivery.
Innovations in nanotechnology have already shown large
medical applications. DDSs are considered to be essential
for overcoming the current limitations of the frequent and
long-term intravitreal injection of drugs with regard to drug
efficacy, and the currently used method of sustained release
of retinal medications. These systems should be flexible for
combining several drugs without the need for multiple proce-
dures with minimizing the invasive procedure for the sus-
tained-release drug devices.
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